Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2021

Graham Laura S, Pritchard Colin C, Schweizer Michael T

Abstract excerpt

Mutational burden is positively correlated with tumor neoantigen load and studies have demonstrated an association between high tumor mutational burden (TMB) and response to checkpoint blockade. On the basis of a phase II study, the anti-PD-1 therapy, pembrolizumab, was given FDA approval for use in any solid tumor with a high TMB (i.e., >10 mutations/megabase) as assessed by the FoundationOne companion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Immunotherapy and Biomarkers

Share to Colorectal Neoplasms

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Neoplastic Syndromes, Hereditary

Source

Open in PubMed Open full text

Identifiers

PMID: 34580112
DOI: 10.1158/1078-0432.CCR-21-3031
PMCID: PMC8678334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.PMID 34580112Read ↗

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read ↗

Tumour mutational burden: clinical utility, challenges and emerging improvements.Semantic proximity Read ↗

Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current EvidenceSemantic proximity Read ↗

Tumour mutational burden: an overview for pathologists.Semantic proximity Read ↗

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Semantic proximity Read ↗

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.Semantic proximity Read ↗

Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.Semantic proximity Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.